Protective effects of sequoyitol on type 2 diabetic rats with liver inflammatory lesions

AIM：To investigate the possible protective effect of sequoyitol on type 2 diabetic rats with liver inflammatory lesions. METHODS：Type 2 diabetic rats were induced by feeding high-fat/high-sugar diet and injecting with a low dose of streptozotocin. Sequoyitol at doses of 12.5, 25 and 50 mg·kg-1·d-1 was orally administered in the model rats. At the end of the experiment, the rats were sacrificed. Serum levels of fasting blood glucose, alanine aminotransferase(ALT), aspartate aminotransferase(AST) and albumin(ALB) were determined. Liver wet was recorded and liver index was calculated. The levels of C-reactive protein(CRP),tumor necrosis factor α(TNF-α) and interleukin 6(IL-6) in the liver tissues were also measured. Real-time PCR was used to determine the mRNA expression of TNF-α. In addition, the pathological changes of the liver were observed with HE staining. RESULTS：Compared with the model rats, treatment with sequoyitol obviously decreased the levels of fasting blood glucose, ALT, AST, ALB, CRP, TNF-α and IL-6, reduced the liver index, down-regulated the mRNA expression of TNF-α in the liver, and ameliorated the pathologic changes of the liver. CONCLUSION：Sequoyitol attenuates liver lesions in type 2 diabetic rats through down-regulation of TNF-α and IL-6 expression.